Scholar Rock Holding Corporation - Common Stock (SRRK)
38.60
+2.13 (5.84%)
NASDAQ · Last Trade: Nov 18th, 11:16 AM EST
Detailed Quote
Previous Close
36.47
Open
36.92
Bid
38.55
Ask
38.66
Day's Range
36.77 - 38.89
52 Week Range
22.71 - 46.98
Volume
664,181
Market Cap
3.66B
PE Ratio (TTM)
-12.22
EPS (TTM)
-3.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,162,172
Chart
About Scholar Rock Holding Corporation - Common Stock (SRRK)
Scholar Rock Holding Corp is a biotechnology company focused on developing innovative therapies for the treatment of serious diseases, particularly those related to muscle and neuromuscular disorders. The company's proprietary approach leverages its knowledge of the biology underlying certain conditions to identify and target specific proteins that play a critical role in disease progression. By developing these targeted therapies, Scholar Rock aims to offer new, effective treatment options for patients who currently have limited alternatives. The company is dedicated to advancing its research and clinical programs while fostering collaboration within the scientific and medical communities. Read More
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences:
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments.
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 17,143 shares of common stock and inducement restricted stock units, covering an aggregate of 12,857 shares of its common stock.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Tuesday, November 18 at 3:30 p.m. GMT in London, UK.
Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open.
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the company granted inducement equity awards covering an aggregate of 114,500 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 65,429 shares of common stock and inducement restricted stock units, covering an aggregate of 49,071 shares of its common stock.
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
